A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy—case report and literature review
CD19-directed CAR T cell therapy shows promise in refractory IIM, offering sustained clinical improvement and a favourable safety profile. The nine reported cases collectively highlight the potential of CAR T cell therapy even in patients with insufficient response to B cell/plasma-cell depleting therapies. Larger studies are needed to evaluate long-term efficacy, safety, and underlying mechanisms of CAR T cell therapy in refractory IIM.
Authors
- Nicolaus Martin Kröger (ORCID: https://orcid.org/0000-0001-5103-9966)
- Martin Krusche (ORCID: https://orcid.org/0000-0002-0582-7790)
- Isabell Haase (ORCID: https://orcid.org/0000-0002-3412-6838)
- Marie‐Therese Holzer (ORCID: https://orcid.org/0000-0002-2064-6728)
- J Richter
- Susanna Carolina Berger
- Ina Kötter (ORCID: https://orcid.org/0000-0002-9262-005X)
- Boris Fehse (ORCID: https://orcid.org/0000-0001-9780-7211)
- Nico Gagelmann (ORCID: https://orcid.org/0000-0002-0891-1744)
- Nikolas Ruffer (ORCID: https://orcid.org/0000-0001-8394-969X)
- Dominic Borie (ORCID: https://orcid.org/0009-0008-3569-2576)
- Francis Ayuk (ORCID: https://orcid.org/0000-0001-6297-1847)
- Johan Seibel
Institutions
- Universität Hamburg (DE)
- Institute for Transfusion Medicine (US)
- University Medical Center Hamburg-Eppendorf (DE)
- HNO Bad Bramstedt (DE)
- German Centre for Cardiovascular Research (DE)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1093/rheumatology/keaf190
- Citations
- 6
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 6.27